Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$252.83
-1.2%
$242.80
$188.08
▼
$282.15
$15.77B0.4703,724 shs566,282 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$64.63
-1.8%
$63.03
$39.71
▼
$73.69
$15.77B0.452.62 million shs2.19 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$91.35
-1.8%
$113.53
$61.22
▼
$134.00
$10.41B0.921.99 million shs1.50 million shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$21.73
-4.3%
$23.49
$8.30
▼
$34.39
$3.68B1.263.46 million shs1.74 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-5.32%-4.16%+9.23%+1.05%+20.65%
Exelixis, Inc. stock logo
EXEL
Exelixis
-3.60%-5.74%+2.24%+21.73%+56.22%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-2.88%-7.58%-25.19%-13.99%+32.44%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
+3.75%-8.61%-10.06%-4.90%+174.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$252.83
-1.2%
$242.80
$188.08
▼
$282.15
$15.77B0.4703,724 shs566,282 shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$64.63
-1.8%
$63.03
$39.71
▼
$73.69
$15.77B0.452.62 million shs2.19 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$91.35
-1.8%
$113.53
$61.22
▼
$134.00
$10.41B0.921.99 million shs1.50 million shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$21.73
-4.3%
$23.49
$8.30
▼
$34.39
$3.68B1.263.46 million shs1.74 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-5.32%-4.16%+9.23%+1.05%+20.65%
Exelixis, Inc. stock logo
EXEL
Exelixis
-3.60%-5.74%+2.24%+21.73%+56.22%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-2.88%-7.58%-25.19%-13.99%+32.44%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
+3.75%-8.61%-10.06%-4.90%+174.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.90
Moderate Buy$312.6723.67% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.41
Hold$58.62-9.31% Downside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.46
Hold$110.1720.60% Upside
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
2.65
Moderate Buy$48.17121.66% Upside

Current Analyst Ratings Breakdown

Latest TNGX, EXEL, ASND, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Set Price Target$130.00
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Boost Price TargetNeutral$79.00 ➝ $81.00
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy$130.00
11/17/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingBuy$300.00
11/16/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy
11/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetOverweight$329.00 ➝ $341.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UpgradeHold (C) ➝ Hold (C+)
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Set Price Target$352.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Reiterated RatingOutperform
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetOverweight$326.00 ➝ $330.00
11/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Set Price Target$330.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.20B13.11N/AN/A$27.69 per share9.13
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.80$2.86 per share22.56$7.52 per share8.59
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B7.46$4.55 per share20.08($0.48) per share-190.31
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$62.38M59.03N/AN/A$5.78 per share3.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$15.3016.5227.60N/A73.26%32.47%13.26%N/A
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.3419.3517.011.7635.45%45.54%33.90%N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.9323.249.320.3626.93%751.81%23.84%N/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$101.59M-$1.37N/AN/AN/AN/A-30.34%-28.28%N/A

Latest TNGX, EXEL, ASND, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.3530-$0.39-$0.0370-$0.39$3.28 millionN/A
11/5/2026Q3 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$2.30$2.39+$0.09$2.01$491.63 million$492.97 million
10/29/2026Q3 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8870$0.94+$0.0530$0.85$646.51 million$658.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.25
2.89
2.29
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.21
3.14
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
3.88
3.60
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/A
39.45
39.45

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
78.99%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
6.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077244.01 million237.67 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423114.01 million111.16 millionOptionable
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
137169.46 million158.44 millionOptionable

Recent News About These Companies

Tango Therapeutics (NASDAQ:TNGX) Stock Falls 7.5% - What's Next?
Tango Therapeutics (TNGX) and The Competition Critical Contrast
Research Analysts Offer Predictions for TNGX FY2026 Earnings
Tango Therapeutics (NASDAQ:TNGX) Stock Price Target Cut by Wedbush

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$252.83 -3.13 (-1.22%)
Closing price 04:00 PM Eastern
Extended Trading
$247.74 -5.09 (-2.01%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$64.63 -1.20 (-1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$66.05 +1.42 (+2.20%)
As of 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$91.35 -1.69 (-1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$91.40 +0.05 (+0.05%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Tango Therapeutics stock logo

Tango Therapeutics NASDAQ:TNGX

$21.73 -0.98 (-4.32%)
Closing price 04:00 PM Eastern
Extended Trading
$21.56 -0.16 (-0.76%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.